o2h Ventures
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Pre-Seed, Seed, Series A, Series B, Growth Stage
Geographical Focus
United States, United Kingdom, Germany, India, France, Italy, Denmark, Switzerland, Spain, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Norway, Finland, Poland, Czech Republic
Industries Focus
- Healthcare
- Artificial Intelligence
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Machine Learning
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immunology
- Genomics
Investment Size:
100,000 to 1,500,000 USD
Investor Details Founded: 2018
o2h Ventures is a UK-based venture capital firm specializing in early-stage biotech investments. The firm focuses on seeding early-stage biotech therapeutics and related AI opportunities, offering investors the opportunity to back promising medical innovations through the Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS).
The firm's investment strategy encompasses various stages, including Pre-Seed, Seed, Series A, Series B, and Growth Stage, with typical investments ranging from £100,000 to £1.5 million. o2h Ventures primarily invests in the United Kingdom, United States, India, and several European countries, targeting sectors such as Biotechnology, Healthcare, Medical Devices, Pharmaceuticals, Artificial Intelligence, Machine Learning, Diagnostics, Genomics, Immunology, Oncology, Neurology, Cardiology, Endocrinology, Infectious Diseases, and Regenerative Medicine.
o2h Ventures operates from Hauxton House, The Mill SciTech Park, Mill Lane, Hauxton, Cambridge, Cambridgeshire, United Kingdom. The firm's leadership includes CEO and Co-Founder Sunil Shah, who has a background in biochemistry and an MBA from Cambridge University, and Director Prashant Shah, a serial entrepreneur with experience in technology and life sciences. The firm is authorized by the Financial Conduct Authority (FRN 812245) and is a member of the Enterprise Investment Scheme Association (EISA).
Requirements
- High-risk tolerance
- Sophisticated and high-net-worth investors
- Diversified investment portfolio strategy
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Atelerix
- CamGene Therapeutics
- Monument Therapeutics
- Visibly
- Zephx
- Cambridge Squared
- Biotech Bikers
- Chaitime Webinars
- Cambridge Stock Exchange Project
- Influencer Bootcamps
Claim this Investor
Are you an official representative of o2h Ventures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim